Thanks Philly guy(Hands on and I are both from Philadelphia originally can only shudder and think how hot and humid Philly is these days)),and along similar lines I recently bought 2k of TMED in the 2s and it is looking good---this press release just came out which gives a basic
rundown of company--they have been around awhile but now may really be ready.
SOURCE: Donner Corp. International
Donner Corp. International Upgrades to Buy
Recommendation on Trimedyne, Inc.
SANTA ANA, Calif., July 27 /PRNewswire/ -- The following is being issued by Donner Corp. International, a member of the
National Association of Securities Dealers, CRD number 37702.
Donner Corp. International, an Investment Banking firm headquartered in Santa Ana, Calif., upgraded its Recommendation to
Buy on Trimedyne, Inc. (Nasdaq: TMED - news), Irvine, Calif. Trimedyne develops, manufactures and markets lasers that are
used in urology, orthopedics, ear, nose and throat surgeries, gynecology and general surgery. Donner cited the recent significant
news that Trimedyne has received clearance from the U.S. Food and Drug Administration to market its OmniTip(TM)
Side-Firing Laser Needle used in a minimally invasive procedure to treat herniated lumbar disks. The product is called the
''Knight Needle.''
The ''Knight Needle'' has also been cleared for sale for other surgical applications, including urology, ear, nose and throat
surgery, gynecology, arthroscopy and general surgery.
Donner also stressed that Trimedyne's 90 percent owned subsidiary, Cardiodyne, Inc., may potentially revolutionize the
treatment of coronary artery disease by using its proprietary laser system that is less expensive, less time-consuming, less
traumatic and a less invasive alternative to balloon angioplasty and bypass surgery. The cost of treating heart disease in the U.S.
annually is estimated at $112 billion.
Cardiodyne's Endoscopic TMLR System(TM), which allows revascularization of the heart at a cost of less than $15,000 a
procedure, is less than half the cost of bypass surgery. Cardiodyne expects to meet foreign regulatory requirements and to
begin marketing this system overseas in late 1999. Donner said the system ''will be especially attractive to those countries
whose healthcare budgets do not permit a sufficient number of expensive bypass surgeries.''
Donner also stressed that Trimedyne's proprietary lasers have distinct advantages over other types of medical lasers. ''The
Holmium laser has a more shallow depth of penetration in tissue, which results in precise vaporization and very little damage to
adjoining tissues,'' the report said.
The Buy Recommendation said Trimedyne has a cosmetic laser in development and new products for use in treating brain
aneurysms and excessive uterine bleeding. ''Trimedyne's growth in urology, the new products that Trimedyne is developing and
the potential of Cardiodyne represent a significant opportunity for stock appreciation in the future,'' the Donner report
concludes.
Copies of the report are available from Donner Corporation at 800/324-6050. Donner issued a Speculative Buy
Recommendation on Trimedyne on Nov. 2, 1998.
(The information contained herein is based on sources believed to be reliable but is not guaranteed by this Company and is
not comprehensive. It is not to be construed as an offer or the solicitation of an offer to sell or buy securities mentioned herein.
The Company, its members, affiliates and employees may have long or short positions, which could be substantial, in securities
discussed or recommended and may purchase, sell, or trade these securities from time to time in the open market or otherwise.
In addition, this Company may from time to time perform investment banking, corporate finance, provide services for, and
solicit investment banking, corporate finance, or other business from the issuers of such securities.)
SOURCE: Donner Corp. International |
